skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Informa pharma logo

Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Pharma Intelligence Logo
Search Icon Pharma Report StoreRecommendationsProduct loginProductLogin
Global Search Configuration

Refine Results

Clear All

Specialism

Show More

Resources

Show More

Show More

Products

Show More

Show More

14 Total results for product and free and sample content found

Datamonitor Healthcare

Pulmonary hypertension research wire

By Daniel Chancellor 01 Mar 2017

Pulmonary hypertension research wire

New clinical data and a deepening treatment algorithm will drive market growth

Topic Research wire

View article

Datamonitor Healthcare

Chronic Lymphocytic Leukemia

By Dominique Fontanilla 15 Feb 2017

While Rituxan-based therapies remain dominant in the first-line treatment setting for early- and late-stage chronic lymphocytic leukemia (CLL), the majority of patients with relapsed or refractory disease receive Imbruvica. 

Topic Research wire

View opinion

Datamonitor Healthcare

Praluent US sales block gives advantage to Amgen's Repatha in dyslipidemia

06 Jan 2017

On 5 January, Amgen secured a court ruling blocking Praluent (alirocumab; Sanofi/Regeneron) from being sold in the US. This ruling clears the way for Amgen’s Repatha (evolocumab) to potentially become the sole proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor in the US market.

Topic Research wire

View opinion

Datamonitor Healthcare

Despite the failure of solanezumab’s EXPEDITION 3 trial, hope for the amyloid hypothesis lingers on

12 Dec 2016

At the 2016 Clinical Trials on Alzheimer’s Disease (CTAD) meeting, Eli Lilly provided a more detailed explanation for the failure of solanezumab in its pivotal EXPEDITION 3 study in mild Alzheimer’s disease.

Topic Research wire Alzheimers

View opinion

Datamonitor Healthcare

AHA 2016: Type 2 diabetes treatment is shifting towards therapies with cardiovascular benefits

22 Nov 2016

Controversies to Consensus session at the 2016 American Heart Association (AHA) Scientific Sessions in New Orleans discussed how recent results from cardiovascular outcomes trials should affect current treatment and regulatory practices.

Topic Research wire

View opinion

Datamonitor Healthcare

AHA 2016: Interim Data from ORION-1 Trial Encourage Further Development of Inclisiran

22 Nov 2016

Inclisiran offers patients a more convenient dosing schedule that may allow it to compete with marketed PCSK9 inhibitors when approved.

Topic Research wire

View opinion

Datamonitor Healthcare

AHA 2016: EFFECT-HF supports use of iron deficiency as an independent therapeutic target in heart failure

22 Nov 2016

Topline results from the Phase III EFFECT-HF study of Injectafer (ferric carboxymaltose; Genesis Pharma/The Galenica Group/Zeria) and its impact on exercise capacity in chronic heart failure patients with iron deficiency were presented at the 2016 American Heart Association (AHA) Scientific Sessions in New Orleans.

Topic Research wire

View opinion

Datamonitor Healthcare

AHA 2016: PIONEER-AF trial results will have minimal effect on Xarelto uptake

18 Nov 2016

Reduced doses of Xarelto were shown to lower the rate of bleeding in the PIONEER-AF trial. However, questions still remain as to how efficacious the smaller doses of Xarelto tested in the trial are at protecting against stroke.

Topic Research wire

View opinion

Datamonitor Healthcare

AHA 2016: Repatha causes atherosclerotic plaque regression, even at very low LDL-C levels

17 Nov 2016

The Phase III GLAGOV trial showed Repatha (evolocumab; Amgen/Astellas) treatment to reduce atherosclerotic plaque burden in an apparently dose-dependent manner, even at very small low-density lipoprotein-cholesterol (LDL-C) levels.

Topic Research wire

View opinion
Show More

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Request a free demo

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.
General enquiry

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now:

Shop now